25.55
-1.45 (-5.37%)
| Previous Close | 27.00 |
| Volume | 3,262,254 |
| Price / Earnings (Forward) | 31.87 |
| Price / Sales | 9.70 |
| Price / Book | 19.42 |
| 52 Weeks Range |
| Profit Margin | -60.95% |
| Operating Margin (TTM) | -37.25% |
| Diluted EPS (TTM) | -1.04 |
| Quarterly Revenue Growth (YOY) | 32.80% |
| Total Debt/Equity (MRQ) | 77.67% |
| Current Ratio (MRQ) | 3.55 |
| Operating Cash Flow (TTM) | -110.94 M |
| Levered Free Cash Flow (TTM) | -66.54 M |
| Return on Assets (TTM) | -18.43% |
| Return on Equity (TTM) | -70.57% |
AIStockmoo Score
| Value 30% | -0.9 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | -0.9 |
| Timing 30% | -0.8 |
| AI Technical info | NA |
| Technical Oscillators info | -2.0 |
| Technical Moving Averages info | 1.0 |
| Candle Patterns info | NA |
| Sentiment 20% | 0.0 |
| Analyst Consensus info | 0.0 |
| News Mood info | NA |
| Smart Money 20% | -1.0 |
| Insider Activity info | -1.0 |
| Institutional Flow info | NA |
| Short Interest info | NA |
| Environment | ×1.21 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -26.9% |
| Pillar Agreement | ×1.25 |
| Not in score | |
| Price Volatility info | 2.3 |
| Final Score | -1.08 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Arcutis Biotherapeutics, Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ARQT | - | - | - | 19.42 |
| VIR | - | - | - | 2.29 |
| RLMD | - | - | - | 2.15 |
| CNTN | - | - | - | 0.290 |
| SLS | - | - | - | 11.78 |
| IMNM | - | - | - | 4.68 |
Select this tab to load the latest available analysis.
|
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.95% |
| % Held by Institutions | 108.79% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BURNETT PATRICK | - | 31.26 | -943 | -29,478 |
| MATSUDA MASARU | - | 33.97 | -41,219 | -1,400,106 |
| WATANABE TODD | - | 31.26 | -4,377 | -136,825 |
| Aggregate Net Quantity | -46,539 | |||
| Aggregate Net Value ($) | -1,566,409 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 33.66 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MATSUDA MASARU | Officer | 04 Nov 2026 | Automatic sell (-) | 40,000 | 34.05 | 1,362,000 |
| MATSUDA MASARU | Officer | 04 Nov 2026 | Option execute | 40,000 | - | - |
| WATANABE TODD | Officer | 02 Nov 2026 | Sell (-) | 4,377 | 31.26 | 136,825 |
| BURNETT PATRICK | Officer | 02 Nov 2026 | Sell (-) | 943 | 31.26 | 29,478 |
| MATSUDA MASARU | Officer | 02 Nov 2026 | Sell (-) | 1,219 | 31.26 | 38,106 |
Recent Signals candle patterns and EMA crosses
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |